Pre-Market Heat Map – July 27, 2026

Monday’s pre-market session is being driven by a mix of biotechnology, quantum computing, space, and defense stocks as investors react to improving geopolitical sentiment.

Oil prices retreated from last week’s highs after reports that Iran has shown willingness to resume diplomatic talks, improving overall risk sentiment and supporting growth-oriented and speculative stocks trending.

Below are the 10 stocks generating the most discussion before the opening bell on July 27, 2026.

1. CAPR — Capricor Therapeutics | FDA AdCom in 48 Hours

Capricor Therapeutics remains one of the market’s most closely watched biotech names with its FDA Advisory Committee meeting scheduled in just two days.

The committee will review the company’s Biologics License Application (BLA) for Deramiocel, a cardiosphere-derived cell therapy for Duchenne Muscular Dystrophy (DMD).

Key Data

Capricor’s stock collapsed in pre-market trading (to ~$6.78) after holding near $19.70 on Friday, as investors fear a negative FDA advisory vote on its Duchenne therapy, Deramiocel. Tomorrow morning (Jul 29 at 9:30am ET) FDA’s Cellular, Tissue & Gene Therapies Advisory Committee will review BLA 125842 for Deramiocel (allogeneic cardiosphere-derived cells) to treat cardiomyopathy in DMD. The primary efficacy endpoint under review is performance on the PUL 2.0 scale (a limb function measure) with left-ventricular ejection fraction (LVEF) as a key secondary. A positive AdCom vote would sharply boost PDUFA approval odds, as the resubmitted BLA targets an Aug 22, 2026 decision date. A negative vote, by contrast, could see CAPR plummet another 30–50%. Retail sentiment on Stocktwits calls this a “binary bet,” and traders have already built large position (note $15.6M shares short = 29.8% float).

CAPR’s fundamentals: Q1 2026 net loss widened to $33.9M (EPS –$0.59) on flat revenue. Cash was $279M as of March. Analysts remain unanimously bullish (100% Buy; avg PT ~$42.4, implying 500% upside even from the pre-market level). Director Karimah Es Sabar exercised options and sold 7,529 shares at $32 in April. All eyes are on Tuesday’s AdCom and the Aug 22 FDA decision.

Risk

A negative advisory committee recommendation could result in significant share price volatility.

2. QBTS — D-Wave Quantum | Nasdaq Listing & Earnings

First Trading Day on Nasdaq

D-Wave Quantum officially begins trading on the Nasdaq exchange after transferring from the New York Stock Exchange.

The company enters its first Nasdaq session following a 13.6% decline during the previous week.

Key Data

D-Wave’s stock is up nearly +9% pre-market on its first day trading on Nasdaq. The quantum computing pioneer officially transferred its listing from NYSE to Nasdaq effective July 27. After closing ~$16.21 on Friday, QBTS is trading around $17.66. New options started trading Tuesday, fueling demand. The Nasdaq debut coincides with growing hype around Trump’s recent quantum initiatives (June 22 EOs on quantum and crypto). D-Wave reports Q2 on Aug 6 (a large ~17% move is implied by options).

QBTS fundamentals:

Market cap ~$6.0B. 5-day was slightly down; 1-month deep correction (–32%). About 62% of Wall Street ratings are Buy (avg PT ~$37). Recent news includes a strategic partnership with AT&T (boosting telecom use cases). Notably, insiders have been heavy sellers: ~$294.5M of insider stock sold over five years. Still, a majority of analysts have a bullish outlook (Strong Buy consensus, PTs in mid-$30s).

Key catalysts:

Moving to Nasdaq (symbol QBTS), Q2 earnings (Aug 6), and continuing federal support for U.S. quantum tech.

Risk

Given high share count and significant insider sell-off, risk is High despite momentum. Investors continue monitoring insider selling activity across major publicly traded quantum computing companies.

3. OMER — Omeros Corp. | J-Code Ramp vs. EU Setback

Commercial Growth for YARTEMLEA

Omeros continues to receive attention following commercial progress for its FDA-approved therapy YARTEMLEA (narsoplimab).

A permanent CMS J-code became effective on July 1, simplifying reimbursement.

Key Data

Omeros jumped ~12.5% pre-market to ~$11.01 after a rally in orphan-drug momentum. In late April, CMS assigned YARTEMLEA (narsoplimab) a permanent J-code (J1289) effective July 1, 2026, greatly easing reimbursement for this microangiopathy therapy. In Q1 2026, Omeros reported $11.1M gross sales of YARTEMLEA (vastly beating the $4.1M consensus) and net income of $56.1M (EPS +$0.78) thanks to a large noncash gain. Adjusted cash burn was $17.1M. With J-code in place, Omeros expects its US launch to accelerate.

The bullish case is tempered by a regulatory setback in Europe: the EMA’s CHMP issued a negative opinion on narsoplimab on June 25, 2026. Omeros immediately announced it would seek a re-examination and an Ad Hoc Expert Committee review. This has not affected U.S. revenues, but adds execution risk. The company also repurchased ~$14.5M of its 2029 convertible notes (9.50%) in July, reducing debt to $40.3M.

Key metrics:

Market cap ~$708M. Stock up 5d +1.7%. Float ~69.8M shs, ~21.6% shorted. Analysts (3): Strong Buy; consensus price target ~$26.4 (range ~$9–45). For example, HC Wainwright’s top PT is $33.

Risks:

Include the EU EMA reversal (could hurt overseas expansion) and financing needs if launch costs remain high. The FDA path: NDA under review with PDUFA late Aug; the J-code now supports US uptake.

4. SPAIF — Sparc AI (OTC) | Verify on EDGAR (Illiquid OTCQB)

OTC Stock Trending Before the Open

SPAIF is Sparc AI Inc., an OTCQB-listed technology company focused on AI-driven navigation for drones. It is not traded on Nasdaq/NYSE and has extremely thin liquidity and wide bid-ask spreads. For example, yesterday’s “news” coverage touted Sparc’s GPS-denied drone system, but actual quote data is unreliable. Traders should verify the exact security on SEC EDGAR – Sparc AI Inc. does not file full SEC reports (likely only Reg D for funding). The OTC ticker represents Sparc AI’s ordinary shares, and PreUSD token trading can drive volatility. Given the lack of official filings, we have no reliable price or float data. Caution is advised: this is effectively a speculative social-media favorite with no institutional backing.

Catalyst: Possibly defense contracts or technology demos.

Risks: OTC status, minimal disclosure, very low volume. If pursuing, check EDGAR and OTCMarkets for corporate announcements.

Investors are encouraged to verify:

• Company information.
• SEC filings.
• Bid-ask spreads.
• Trading catalyst.

OTC securities often experience wider spreads and higher volatility than exchange-listed stocks.

5. FBRX — Forte Biosciences | $77 Argenx Acquisition Arb

$77 Per Share Acquisition

Forte Biosciences remains one of the biggest pre-market movers following its announced acquisition by Argenx.

Key Data

Forte spiked ~+39.5% pre-market after Argenx (ARGX) announced a $2.2 billion all-cash tender offer at $77/share for FBRX. That deal price is a ~41% premium to Friday’s closing price. With the market still about $11 below the bid, Merger arbitrageurs are moving in (current implied upside ~62%). Both boards have approved the deal; closing is expected in Q3 2026, subject to majority tender and antitrust clearance.

FBRX snapshot:

It was ~$54.78 Friday; pre-market $76.44. Shares out 20.48M. Short interest modest (11.6% float). Prior to the bid, analysts were already bullish (Barclays OW / $74 PT, Evercore $65, Guggenheim $75). With the bid, the focus is now on deal risk. There is no other near-term catalyst; key dates are antitrust review (15-day HSR filed) and the tender offer expiration (expected in Q3).

Risks:

If regulators delay or block the deal, the stock would fall back to pre-announcement levels ($54). Hedge funds have piled in (23 reported in Q1, up from 14 in Q4). The credit profile is clean (no debt). Arb spread remains wide (~62%) reflecting execution uncertainty. In summary, FBRX is effectively a buyout arb: upside locked to $77 pending approval, but with deal risk.

6. RKLB — Rocket Lab USA | $266M Space Contract + Aug Earnings

Government Contract and Upcoming Earnings

Rocket Lab remains active after securing a government contract and ahead of second-quarter earnings.

Key Data

Rocket Lab is trading up ~5% pre-market on news of a new U.S. Space Force contract. The $266M fixed-price award covers 12 suborbital launch vehicles (six optional) for hypersonic and missile defense missions. The first of these launches is not expected before late 2026, so the financial impact will start in FY2027. This award significantly boosts RKLB’s already-strong backlog (which was ~$1.42B at Q1’26).

Key stats:

RKLB closed ~64, trading near $66. Market cap ~ $39.6B. Shares out ~579M, float similar. Short interest is relatively low (~8.65% of float). In Q1, backlog was 2.4 years of revenue ($1.42B). Analysts are optimistic: 85% rate it Buy (13/17) with avg price target ~$111. Next catalyst is Q2 earnings (Aug 6) and any Iridium merger updates (Iridium acquisition announced June 29, $8B all-stock). The RSI suggests the pullback to mid-$60s was an entry; Fed rate drop hopes and defense spending are tailwinds. Long-term, market will watch launch cadence and execution of the LEO constellation acquisitions. Overall, Rocket Lab remains a market favorite with multiple government and commercial backlogs.

7. LEGN  — Legend Biotech | CARVYKTI Ramp in Focus

CARVYKTI Commercial Expansion

Legend Biotech, co-developer of CARVYKTI (cilta-cel) for multiple myeloma, has no major news today but remains on watch due to growing CAR-T adoption. The stock is down ~6–7% pre-market (trading ~$20.75; down –6.6%). Legend’s recent drivers include FDA approval of CARVYKTI and expanding use in 2L/3L myeloma. Legend co-markets CARVYKTI with Janssen (J&J), splitting U.S. profits (Legend gets royalties and milestones) and retaining Greater China rights. In Q1 2026, Legend reported a 62% jump in net sales of CARVYKTI to ~$597M, fueling big earnings beats. Challenges include manufacturing capacity and competition from BMS’s Abecma.

Key stats:

Market Cap ~$4.13B, shares ~193M. The float is ~176.6M. Short ~8.0%. Performance: –4.3% in past 5 days, –24.4% in 1M. No upcoming data release today; next catalyst is Q2 results (likely late Aug). Analysts (17 in total) have mixed views (some upgrades after CAR-T data; see Analyst Ratings chart). A June 2026 readout showed 100% responses in a CARVYKTI lymphoma trial (non-Hodgkin), which could be a growth driver. The U.S. J&J partnership is a key asset (co-promotion), but Legend may be diluted as J&J funds most costs. High-level investors watch Legend as a second-wave biotech leader (now a Fortune 100 co.) – but today the stock is volatile in sympathy with biotech deltas.

The company remains focused on treating multiple myeloma through its CAR-T therapy.

Areas investors continue monitoring include:

• Manufacturing capacity.
• Commercial adoption.
• Market share expansion.

8. IONQ — IonQ, Inc. | Top Revenue Growth in Quantum Trio

Revenue Growth and Quantum Recovery

IonQ continues its impressive post-results rally. Q1 2026 revenue jumped 755% YoY, driving its stock to recover ~+1% today ($32.8) after last week’s sell-off (it was near $28 late last week). Pre-market, IONQ is around $32.80 (essentially flat). Market cap ~$12.25B, with ~373M shares. Up 5d modestly; 1M performance flat. Analyst sentiment is mostly Buy (73% buy ratings); Benchmark Capital initiated coverage with a $60 target. No new earnings until Aug 5.

Government funding remains a background tailwind: IonQ led a DOE/AFRL “quantum in space” initiative (see DOE MOU, Sept 2025) and won a $25.5M USAF contract in 2023. Plus last month, the Commerce Dept announced LOIs for $2.01B in total quantum R&D – Rigetti and others ($100M each) – but IonQ was not on that list. So while Trap-Ion leaders Quantinuum and Rigetti have direct CHIPS Act funding, IonQ has not yet publicized a CHIPS award. Nonetheless, given its technical lead (highest-fidelity qubits) and CEO’s Capitol Hill advocacy, it benefits from pro-quantum policy. Short interest is ~12.7% of float (47M shares). Catalysts: Aug 5 Q2 earnings, any government announcements, and broader tech sentiment.

Key Highlights

• Q1 2026 revenue increased 755% year over year.
• Benefits from June 22 quantum executive orders.
• Recovering after recent weakness.
• Improving geopolitical sentiment supported pre-market trading.

Risk

Investors continue monitoring insider selling across publicly traded quantum companies.

9. ANTHZZX— Anthropic Token (OTC) | Crypto/Tokenized Stock

Verify Before Trading

ANTHZZX is another OTC security requiring additional verification before trading.

Type: OTC “tokenized” equity. ANTHZZX is not a Nasdaq/NYSE ticker but a crypto-style token for Anthropic Inc. (an AI company). On OTC, it’s represented as a “pre-stock” share (via tZERO). It trades like a digital asset: e.g. quoted around $284.66 (down 5.68%). This reflects abstract value on Anthropic’s last funding round, not SEC-registered stock. Important: There are no SEC filings for Anthropic as a public company, and this token lacks formal disclosure. Trading ANTHZZX is effectively speculating on private equity. Spread and liquidity are extremely poor. Before considering ANTHZZX, investors should verify on EDGAR (Anthropic has only Regulation D filings, not an S-1) and understand this is an unregulated OTC crypto-like instrument.

Risk is EXTREME. We cite no price data here (it is misleading); this listing is for informational completeness only.

Investors should confirm:

• Company information.
• SEC filings.
• Security type.
• Current trading catalyst.

Thin liquidity and limited disclosure can increase trading risk.

10. RGTI — Rigetti Computing | $100M CHIPS LOI + Policy Tailwind

Federal Funding Catalyst

Rigetti surged ~+5.2% pre-market to ~$14.88 on renewed enthusiasm after last month’s CHIPS Act news. On May 21, Rigetti announced a letter of intent with the U.S. Dept. of Commerce for up to $100M in quantum R&D funding over three years. The official NIST release confirms “Rigetti will receive up to $100M in planned funding” to tackle scaling bottlenecks in superconducting qubits. This policy breakthrough (with DOC getting an equity stake) sent RGTI +30.6% on May21, and the momentum carries into today. Shares had recently sold off about 5% (to $14.15), but flipped higher on Monday.

RGTI metrics: Market cap ~$4.70B. Outstanding 332.3M. Short float ~18.8%. Institutional owners ~53%. Analysts’ consensus was moderate (average rating 1.69/5, target ~$31, though some firms are bearish due to cash burn). Next catalyst is Q2 results (Aug 6). Besides funding, watch execution: Achieving practical error-corrected qubits remains a challenge. For now, CHIPS funding is a bullish tailwind for Rigetti (alongside IonQ and D-Wave in the U.S. quantum strategy). Trading RGTI now is effectively a policy play: positive on the LOI, but note the Commerce stake will dilute shareholders.

Key Highlights

• Up to $100 million over three years under the CHIPS Act.
• Recovery following recent declines.
• Benefits from improving market sentiment.
• Continues developing gate-model quantum computing technology.

The funding provides additional support as the company continues developing its quantum computing platform.

Bonus: Frequency Electronics (FEIM)

Defense Technology Focus

Frequency Electronics also appeared among the stocks attracting attention before the market open.

The company manufactures precision timing products used in:

• Defense systems.
• GPS technology.
• Satellite communications.
• Missile guidance.
• Space applications.

The stock continues benefiting from investor interest in defense-related companies.

Pre-Market Snapshot – Monday, July 27, 2026

1-Day Movers (Pre-Market % Change)

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is intended solely for informational and journalistic purposes and does not constitute financial, investment, or legal advice. All investments involve risk, including the potential loss of capital. Biotechnology and quantum computing stocks may experience significant volatility due to regulatory decisions, clinical trial outcomes, earnings releases, and other company-specific events. OTC securities involve additional risks, including lower liquidity, wider bid-ask spreads, and limited public disclosure. Pre-market prices reflect information available before the July 27, 2026 market open and may change rapidly during trading. Investors should conduct their own due diligence before making any investment decisions.

About The Author

Lovedeep Kaur

Digital Marketer, Writer, and Project Management Specialist!

See author's posts